AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32380535 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 509
Study 32380535 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine analysis of sAML-like gene mutations
Number of subjects: 509
Study 32380537 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlilumab (0.1, 0.3, 1, 3, or 10 mg/kg IV) as a single dose with a 28-day observation period, followed by weekly dosing (4 doses per cycle, up to 5 cycles)
Number of subjects: 30
Study 32380537 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlilumab (0.3 mg/kg every 3 weeks, 4 doses per cycle, up to 5 cycles) in an expansion cohort of 4 patients with Hodgkin lymphoma
Number of subjects: 30
Study 32380536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense immunochemotherapy with early systemic CNS prophylaxis (2 courses of high-dose methotrexate, biweekly rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14), followed by 4 courses of R-CHOEP and 1 course of high-dose cytarabine with R, plus intrathecal liposomal cytarabine at courses 1, 3, and 5)
Number of subjects: 139
Study 32380536 — intervention group
Group type: COMPARATOR
Intervention: Previous trial with systemic CNS prophylaxis given after 6 courses of biweekly R-CHOEP
Number of subjects: 139
Study 32380538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib (targeted mutant IDH1 enzyme inhibitor)
Number of subjects: 174
Study 32380538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 174
Study 32380978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-provided HIV point-of-care testing (POCT) program
Number of subjects: 123
Study 32381080 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-mycobacterial treatment
Number of subjects: 114
Study 32381080 — intervention group
Group type: COMPARATOR
Intervention: Observation without treatment
Number of subjects: 114
Study 32381098 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinbudan tablet (QBDT) as adjunct therapy with standard anti-TB regimen (isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin for 2 months, followed by isoniazid, rifampicin, ethambutol for 6 months)
Number of subjects: 181
Study 32381098 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard anti-TB regimen
Number of subjects: 181
Study 32381098 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinbudan tablet (QBDT) as adjunct therapy with standard anti-TB regimen
Number of subjects: 181
Study 32381107 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal infections
Number of subjects: 316
Study 32381107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary infections
Number of subjects: 316
Study 32381107 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin/Soft Tissue infections
Number of subjects: 316
Study 32381107 — intervention group
Group type: EXPERIMENTAL
Intervention: Genitourinary infections
Number of subjects: 316
Study 32381107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular infections
Number of subjects: 316
Study 32381452 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-component or 2-component prosthesis with subtalar arthrodesis
Number of subjects: 23
Study 32381495 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-observed therapy (VOT)
Number of subjects: 197
Study 32381495 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based directly observed therapy (DOT)
Number of subjects: 197
Study 32381630 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg orally per day for 12 months
Number of subjects: 60
Study 32381630 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally per day for 12 months
Number of subjects: 60
Study 32382685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 1602
Study 32382685 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 1602
Study 32382685 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 1602
Study 32382714 — intervention group
Group type: EXPERIMENTAL
Intervention: H4:IC31 vaccine (2 doses IM 56 days apart)
Number of subjects: 84
Study 32382714 — intervention group
Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (2 doses IM 56 days apart)
Number of subjects: 84
Study 32382714 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination (single dose ID)
Number of subjects: 84
Study 32382714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 84
Study 32382720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 388
Study 32382720 — intervention group
Group type: COMPARATOR
Intervention: Standard 10 Hz rTMS
Number of subjects: 388
Study 32382759 — intervention group
Group type: EXPERIMENTAL
Intervention: African American adults
Number of subjects: 36
Study 32382759 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic White adults
Number of subjects: 36
Study 32382759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 32382869 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenesis imaging with tracers
Number of subjects: 10
Study 32382869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracers used for imaging
Number of subjects: 10
Study 32383099 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 32383099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative approaches (e.g., prevalence function, Q-TWiST, ToxT, recurrent event approaches)
Number of subjects: 0
Study 32383192 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (first-line treatment)
Number of subjects: 139
Study 32383192 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine, cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP), fludarabine, or ibrutinib (second-line treatment)
Number of subjects: 139
Study 32383296 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporally Feathered Radiation Therapy (TFRT)
Number of subjects: 1
Study 32383296 — intervention group
Group type: COMPARATOR
Intervention: Non-TFRT IMRT plan
Number of subjects: 1
Study 32383391 — intervention group
Group type: EXPERIMENTAL
Intervention: RF/PF (40 patients)
Number of subjects: 76
Study 32383391 — intervention group
Group type: EXPERIMENTAL
Intervention: PF/PF (36 patients)
Number of subjects: 76
Study 32383679 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored complex intervention including a dialogue tool and a workshop on UTI for nursing home staff
Number of subjects: 1274
Study 32383679 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1274
Study 32383840 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-peripapillary atrophy (B-PPA) present in eyes developing GA
Number of subjects: 490
Study 32383840 — intervention group
Group type: COMPARATOR
Intervention: Beta-peripapillary atrophy (B-PPA) absent in eyes without GA
Number of subjects: 490
Study 32383840 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater circumferential extent of sclera/choroidal blood vessels B-PPA
Number of subjects: 490
Study 32383840 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-peripapillary atrophy (B-PPA)
Number of subjects: 490
Study 32383840 — intervention group
Group type: COMPARATOR
Intervention: Patients without B-PPA
Number of subjects: 490
Study 32384051 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Attachment-Based Compassion Therapy (iABCT)
Number of subjects: 35
Study 32384343 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients
Number of subjects: 133
Study 32384433 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 30
Study 32384433 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 32384454 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model (Salut+Social) with improved coordination between social and healthcare sectors using ICT tools for 6 months
Number of subjects: 141
Study 32384454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 141
Study 32384454 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver experience evaluation
Number of subjects: 141
Study 32384876 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutemetamol PET imaging
Number of subjects: 208
Study 32384876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical amyloid deposition
Number of subjects: 208
Study 32384884 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine treatment for 8 weeks
Number of subjects: 78
Study 32385062 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to environmental chemicals (perfluoroalkyl substances, phenols, phthalates, flame retardants)
Number of subjects: 441
Study 32385062 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to environmental chemicals
Number of subjects: 441
Study 32385089 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transport to ECCs
Number of subjects: 236
Study 32385089 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transport to iECC (within 20 miles)
Number of subjects: 236
Study 32385089 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transport to iECC (≤20 miles)
Number of subjects: 236
Study 32385089 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transport to ECCs (≤20 miles)
Number of subjects: 236
Study 32385089 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass to iECC modeling under 20 miles
Number of subjects: 236
Study 32385144 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapic vaccine comprising phosphorylated BCAR3 peptide
Number of subjects: 0
Study 32385144 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapic vaccine comprising phosphorylated IRS2 peptide
Number of subjects: 0
Study 32385529 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncalcified plaque burden
Number of subjects: 340
Study 32385529 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density plaque burden
Number of subjects: 340
Study 32385529 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually identified plaque in SB segment
Number of subjects: 340
Study 32385580 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs) initiating weight management conversations
Number of subjects: 1501
Study 32385580 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of obesity as a chronic disease
Number of subjects: 1501
Study 32385580 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsibility for weight loss
Number of subjects: 1501
Study 32385580 — intervention group
Group type: EXPERIMENTAL
Intervention: Time before discussing weight with HCP
Number of subjects: 1501
Study 32385580 — intervention group
Group type: EXPERIMENTAL
Intervention: HCPs' perception of patient motivation
Number of subjects: 1501
Study 32385580 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment time limitations
Number of subjects: 1501
Study 32385603 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglycaemic intravenous glucose infusions (IGIVI)
Number of subjects: 23
Study 32385603 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose administration
Number of subjects: 23
Study 32385604 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 3576
Study 32385604 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 3576
Study 32385604 — intervention group
Group type: COMPARATOR
Intervention: Any fatty acid
Number of subjects: 3576
Study 32385645 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32385714 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK7 inhibitors (CDK7i)
Number of subjects: 0
Study 32385714 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CDK7i with other targeted cancer therapies (BET inhibitors, BCL2 inhibitors, hormone therapies)
Number of subjects: 0
Study 32385774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon pulmonary vein isolation (PVI)
Number of subjects: 0
Study 32385774 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency cavo-tricuspid isthmus (CTI) ablation
Number of subjects: 0
Study 32385824 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lateral displacement of the skin
Number of subjects: 40
Study 32385824 — intervention group
Group type: EXPERIMENTAL
Intervention: 30° external rotation
Number of subjects: 40
Study 32385824 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight leg raised to 30°
Number of subjects: 40
Study 32385824 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee and hip flexed to 90°
Number of subjects: 40
Study 32385845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% sirolimus gel applied twice daily for > 52 weeks (maximum 136 weeks)
Number of subjects: 94
Study 32385845 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% sirolimus gel
Number of subjects: 94
Study 32386106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy records adherence
Number of subjects: 34
Study 32386106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean corpuscular volume (MCV) adherence
Number of subjects: 34
Study 32386106 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal hemoglobin (HbF) adherence
Number of subjects: 34
Study 32386106 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine assay adherence
Number of subjects: 34
Study 32386106 — intervention group
Group type: COMPARATOR
Intervention: Video directly observed therapy (VDOT) adherence
Number of subjects: 34
Study 32386199 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicuspid aortic valve (BAV)
Number of subjects: 141
Study 32386199 — intervention group
Group type: COMPARATOR
Intervention: Tricuspid aortic valve (TAV)
Number of subjects: 141
Study 32386199 — intervention group
Group type: EXPERIMENTAL
Intervention: BAV
Number of subjects: 141
Study 32386199 — intervention group
Group type: COMPARATOR
Intervention: TAV
Number of subjects: 141
Study 32386226 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 171
Study 32386512 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically Healthy Obese (MHO)
Number of subjects: 0
Study 32386512 — intervention group
Group type: COMPARATOR
Intervention: Metabolically Unhealthy Obese (MUO)
Number of subjects: 0
Study 32386512 — intervention group
Group type: COMPARATOR
Intervention: Normal Weight (NW)
Number of subjects: 0
Study 32386512 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive metabolic profiling
Number of subjects: 0
Study 32386566 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0
Study 32386568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg) plus carboplatin and nab-paclitaxel (100 mg/m²) as neoadjuvant treatment.
Number of subjects: 30
Study 32386568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and nab-paclitaxel.
Number of subjects: 30
Study 32386745 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 270
Study 32386745 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental report of severe side-effects three days after vaccination
Number of subjects: 270
Study 32386745 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry about side-effects one month after vaccination
Number of subjects: 270
Study 32386744 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial drugs
Number of subjects: 0
Study 32386744 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32387010 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVAX therapeutic HIV vaccine
Number of subjects: 0
Study 32387378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 100
Study 32387522 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 3 portable sleep study
Number of subjects: 263
Study 32387522 — intervention group
Group type: COMPARATOR
Intervention: Level 1 polysomnography
Number of subjects: 263
Study 32387546 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually Initiated workflow
Number of subjects: 32
Study 32387546 — intervention group
Group type: COMPARATOR
Intervention: Clarity proprietary software
Number of subjects: 32
Study 32387572 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with midline incisional hernia
Number of subjects: 36
Study 32387572 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without hernia)
Number of subjects: 36
Study 32387696 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined basophil activation test (BAT) using a dry and room temperature stable reagent technology, 15 min incubation at 37 °C, 4 pipetting steps, and analyzed by flow cytometry.
Number of subjects: 0
Study 32387696 — intervention group
Group type: EXPERIMENTAL
Intervention: New BAT procedure transposed into a 96 well plate format.
Number of subjects: 0
Study 32387696 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterization of ex vivo basophil reactivity using 8 dilution points with 5 μL of blood per point.
Number of subjects: 0
Study 32388060 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry data collection from 232 MG patients
Number of subjects: 232
Study 32388653 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 15
Study 32388653 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 15
Study 32389183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) and glecaprevir-pibrentasvir (300 mg/120 mg) given one dose 6-12 hours before transplant and once a day for 7 days after surgery (total of 8 doses)
Number of subjects: 30
Study 32389229 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews and smartphone/tablet app reporting
Number of subjects: 27
Study 32390114 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocyte clone size < 10%
Number of subjects: 4439
Study 32390114 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocyte clone size ≥ 10%-< 50%
Number of subjects: 4439
Study 32390114 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocyte clone size ≥ 50%
Number of subjects: 4439
Study 32390114 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 4439
Study 32390133 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein-based nutritional supplements
Number of subjects: 1278
Study 32390227 — intervention group
Group type: EXPERIMENTAL
Intervention: LENT score
Number of subjects: 130
Study 32390227 — intervention group
Group type: EXPERIMENTAL
Intervention: modified-LENT score
Number of subjects: 130
Study 32390227 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMISE score
Number of subjects: 130
Study 32390227 — intervention group
Group type: EXPERIMENTAL
Intervention: SELECT model
Number of subjects: 130
Study 32390277 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily for 7 days in a 28-day cycle)
Number of subjects: 30
Study 32390533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker-mediated QRS widening with gradual desynchronization of LV contraction
Number of subjects: 34
Study 32390533 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide QRS rhythm ensured by dual pacing, dual sensing, and dual response to sensing with short AVD
Number of subjects: 34
Study 32390569 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAD (N=25)
Number of subjects: 25
Study 32390569 — intervention group
Group type: COMPARATOR
Intervention: Patients without PAD (N=7)
Number of subjects: 25
Study 32390591 — intervention group
Group type: EXPERIMENTAL
Intervention: Am Mindfulness-Based Cancer Survivorship-MBCS-Journey (app-based mindfulness intervention)
Number of subjects: 83
Study 32390591 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 83
Study 32390862 — intervention group
Group type: EXPERIMENTAL
Intervention: HCM patients
Number of subjects: 0
Study 32390862 — intervention group
Group type: COMPARATOR
Intervention: Ischemic cardiomyopathy (ICM) with VT
Number of subjects: 0
Study 32390862 — intervention group
Group type: COMPARATOR
Intervention: Ischemic cardiomyopathy (ICM) no VT
Number of subjects: 0
Study 32390862 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 32391157 — intervention group
Group type: EXPERIMENTAL
Intervention: MDW > 20.0
Number of subjects: 2158
Study 32391157 — intervention group
Group type: COMPARATOR
Intervention: MDW ≤ 20.0
Number of subjects: 2158
Study 32391374 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute reduction in dietary protein intake (5 days)
Number of subjects: 0
Study 32391374 — intervention group
Group type: COMPARATOR
Intervention: Habitual protein intake (control group)
Number of subjects: 0
Study 32391524 — intervention group
Group type: EXPERIMENTAL
Intervention: COAST-IS intervention
Number of subjects: 0
Study 32391524 — intervention group
Group type: COMPARATOR
Intervention: Learning collaborative only (control)
Number of subjects: 0
Study 32392298 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual glucocorticoid (GC) production
Number of subjects: 192
Study 32392298 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual mineralocorticoid (MC) production
Number of subjects: 192
Study 32392298 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak cortisol response
Number of subjects: 192
Study 32392316 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetic retinopathy (no-DR)
Number of subjects: 192
Study 32392316 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with increasing severity of diabetic retinopathy (mild, moderate/severe, proliferative)
Number of subjects: 192
Study 32392512 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids (prednisolone-equivalent dose)
Number of subjects: 71642
Study 32392512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoid prednisolone-equivalent dose
Number of subjects: 71642
Study 32392558 — intervention group
Group type: EXPERIMENTAL
Intervention: NETest (multigene assay comprising 51 circulating NET-specific transcripts)
Number of subjects: 222
Study 32392558 — intervention group
Group type: EXPERIMENTAL
Intervention: NETest integrated with epigenome/metastasome levels
Number of subjects: 222